Adverse Event Reporting Delay Is Most Common Cause Of FDA Postmarketing Citations
This article was originally published in The Pink Sheet Daily
Failure to develop written procedures and issues of non-reporting are also frequently cited by FDA’s Postmarketing Adverse Drug Experience Reporting Compliance Program.
You may also be interested in...
Health plans should account for the rise in utilization that occurs with use of mail-order pharmacy when deciding if mail order saves money, Ohio Public Employees Retirement System Director of Healthcare Scott Streator said at the recent Academy of Managed Care Pharmacy Educational Conference in Chicago
Declines in Lipitor's prescription volume due to the presence of generic simvastatin are being offset by price increases, Pfizer says
Pfizer CEO Jeffrey Kindler has opened the door to sales force reductions as part of the firm's latest cost-cutting initiative, announced Oct. 1